Loading
Hydrophilic next-generation linkers have built-in sugars or polyethylene glycol that let ADCs carry more payload without clumping, and they resist efflux pumps.
Glucuronide-triggered linkers (cleaved by beta-glucuronidase), PEGylated linkers and sulfatase- or phosphatase-triggered designs increase hydrophilicity so drug-to-antibody ratios of eight are stable, reduce liver clearance and can yield released species that are poorer efflux-pump substrates. Several appear in next-generation topoisomerase-I and tubulin ADCs from Chinese and US developers.
Sac-TMT carries T030, a belotecan-derived TOP1 inhibitor; belotecan shown.
Showing the molecule this term concerns: Sacituzumab tirumotecan.
Shares Drug efflux pumps (ABC transporters), Sacituzumab tirumotecan, Antibody-drug conjugate (ADC).
Shares Drug efflux pumps (ABC transporters), Sacituzumab tirumotecan, Antibody-drug conjugate (ADC).
Shares Drug-to-antibody ratio (DAR), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Antibody-drug conjugate (ADC).